Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib

Similar Items

• Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays
  od: Weber, Britta, i dr.
  Izdano: (2014)
• The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
  od: Demuth, Christina, i dr.
  Izdano: (2018)
• Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib
  od: Wang, Xiaofei, i dr.
  Izdano: (2017)
• Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients()
  od: Winther-Larsen, Anne, i dr.
  Izdano: (2016)
• The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
  od: Jakobsen, Kristine Raaby, i dr.
  Izdano: (2016)